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A B S T R A C T
Tobacco use, and in particular cigarette smoking, is the single largest preventable cause of cancer in the
European Union (EU). All tobacco products contain a wide range of carcinogens. The main cancer-causing
agents in tobacco smoke are polycyclic aromatic hydrocarbons, tobacco-speciﬁc N-nitrosamines, aromatic
amines, aldehydes,andcertainvolatileorganiccompounds.Tobaccoconsumersarealsoexposedtonicotine,
leading to tobacco addiction in many users. Cigarette smoking causes cancer in multiple organs and is the
main cause of lung cancer, responsible for approximately 82% of cases. In 2012, about 313,000 new cases of
lungcancerand268,000 lungcancerdeathswerereported intheEU;28%ofadults intheEUsmokedtobacco,
and the overall prevalence of current use of smokeless tobacco products was almost 2%. Smokeless tobacco
products, a heterogeneous category, are also carcinogenic but cause a lower burden of cancer deaths than
tobacco smoking. One low-nitrosamine product, snus, is associatedwithmuch lower cancer risk than other
smokeless tobacco products. Smoking generates second-hand smoke (SHS), an established cause of lung
cancer, and inhalation of SHS by non-smokers is still common in indoorworkplaces aswell as indoor public
places, and more so in the homes of smokers. Several interventions have proved effective for stopping
smoking; the most effective intervention is the use of a combination of pharmacotherapy and behavioural
support. Scientiﬁc evidence leads to the following two recommendations for individual actionon tobacco in
the4theditionof theEuropeanCodeAgainst Cancer: (1) ‘‘Donot smoke.Donotuse any formof tobacco’’; (2)
‘‘Make your home smoke-free. Support smoke-free policies in your workplace’’.
 2015 International Agency for Research on Cancer; Licensee ELSEVIER Ltd https://creativecommons.org/
licenses/by-nc-nd/3.0/igo/1. Tobacco use and exposure to second-hand smoke in Europe
1.1. Major form of tobacco use: cigarette smoking
Smoking is by far the most common way of using tobacco
in Europe, and commercially manufactured cigarettes are the§ This is an Open Access article published under the CC BY NC ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
provided the original source is properly cited. This article shall not be used or
reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
* Corresponding author at: IARC European Code Against Cancer Secretariat,
150 Cours Albert Thomas, 69372 Lyon Cedex 08, France. Tel.: +33 04 72 73 84 85.
E-mail address: secretariat-cancer-code-europe@iarc.fr (M.E. Leon).
http://dx.doi.org/10.1016/j.canep.2015.06.001
1877-7821/ 2015 International Agency for Research on Cancer; Licensee ELSEVIER Ltpredominant product used by smokers. Recently, the overall crude
prevalence of cigarette smoking in the European Union (EU) has
decreased. In 2002, smoking prevalence in the 15 EU Member
States was 39%, dropping to 28% in 2012 when the EU comprised
27 Member States (EU-27) [1,2]. However, smoking prevalence is
still alarmingly high in some countries, and the potential for
further reduction remains huge across the EU. In addition, smoking
prevalence remains very high in low-income and disadvantaged
groups across Europe, exacerbating smoking-induced health
inequalities [3]. A 2010 population-based representative survey
of tobacco use involving about 18,000 respondents aged15 years
in 18 European countries using the same questionnaire examined
these differences (Table 1). The Pricing Policy and Control of
Tobacco in Europe (PPACTE) survey revealed smoking prevalence
estimates ranging between 15.7% and 44.3% in men (mean, 30.6%)
and between 11.6% and 38.1% in women (mean, 24.1%) [4],d https://creativecommons.org/licenses/by-nc-nd/3.0/igo/
Table 1
Country-speciﬁc prevalence of current smoking (%) in the population aged 15 years
or over, overall and by gender, male-to-female smoking prevalence ratio (M/F), and
current-to-ex-smoking prevalence ratio (C/E) in 18 selected European countries.
From Gallus et al. [4].
N Smoking prevalence (%) M/F C/E
Total Men Women
Totala 18,056 27.2 30.6 24.1 1.27 1.70
Country
Albania 1000 26.1 40.2 11.6 3.47 4.28
Austria 1001 30.4 37.6 23.9 1.57 1.97
Bulgaria 1027 40.9 44.3 37.7 1.18 2.66
Croatia 948 26.6 31.3 22.5 1.39 1.83
Czech Republic 1000 29.1 35.9 22.6 1.59 2.40
England 1030 24.9 26.5 23.3 1.14 1.03
Finland 962 26.3 33.9 18.8 1.80 0.96
France 1029 27.5 30.9 24.4 1.27 1.34
Greece 965 38.9 43.7 34.0 1.29 3.38
Hungary 1002 35.5 42.7 28.6 1.49 3.87
Ireland 1008 36.0 33.9 38.1 0.89 2.14
Italy 1005 22.0 25.8 18.5 1.39 2.07
Latvia 1061 28.8 42.9 16.3 2.63 2.03
Poland 938 28.0 33.0 23.1 1.43 3.43
Portugal 1000 32.4 35.7 29.4 1.21 2.13
Romania 1080 26.1 34.9 17.7 1.97 2.18
Spain 1000 28.6 26.2 31.0 0.85 1.55
Sweden 1000 16.3 15.7 17.0 0.92 0.68
a Prevalence estimates for the overall populationwere computed weighting each
country in proportion to the country-speciﬁc population aged 15 years or over.
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female smoking prevalence ratios showed countries where
smoking was more common in men (e.g. ratio: 3.5 in Albania),
similar in both sexes (ratio: 1.1 in England) or slightly higher in
women (ratio: 0.85 in Spain). The highest smoking prevalence
overall in the European countries covered was seen in the age
group 25–44 years, in both men and women (39.8% and 32.0%,
respectively). Overall, 16.3% and 9.0% of male and female current
smokers, respectively, reported smoking 25 cigarettes per day
[5]. Thus, a large number of men and women in Europe in 2010
(PPACTE survey) and in 2012 (Eurobarometer survey) [2] were
cigarette smokers, with a sizeable proportion of these reporting
high levels of smoking.
1.2. Smoking products other than cigarettes and other forms of
tobacco used in Europe
Smoking products other than manufactured cigarettes have
recently become more popular in Europe. The use of hand-rolled
cigarettes has become more common among smokers in some
European countries, including England (27.3%), France (16.5%) and
Finland (13.6%), with overall about 10.4% of current smokers using
predominantly hand-rolled cigarettes in the 18 countries included
in the PPACTE survey [6]. The General Household Survey of 2008 in
Great Britain indicated that 28% of smokers used hand-rolled
cigarettes, conﬁrming the frequent use of this type of cigarette
among smokers also in the period before the PPACTE survey
[7]. The market segment corresponding to ﬁne-cut tobacco for
hand-rolled cigarettes, among all tobacco produced for consump-
tion, increased in most EU countries between 2002 and 2010 but
stayed under 10% in more than half of EU countries in 2010 [8],
supporting a trend towards greater use of hand-rolled cigarettes
while corroborating the dominance of manufactured cigarettes
among smokers. This trend has been driven to a great extent by the
lower excise tax rate traditionally applied to ﬁne-cut tobacco for
hand-rolled cigarettes, which has translated into lower product
prices and an incentive towards product substitution after
increases in the price of manufactured cigarettes.Other forms of smoking – such as pipe smoking, smoking of
small cigars or cigarillos, andwater-pipe smoking – are also used in
the EU. Cigar and pipe smoking are relatively uncommon in the EU
comparedwith cigarette smoking. According to the Eurobarometer
survey in 2012 1% of smokers reported smoking cigars daily and an
equal proportion reported smoking cigars weekly. Percentages for
pipe smoking were identical [2]. Results from the Eurobarometer
survey in 2012 indicated that 16% of respondents had tried water-
pipe smoking at least once, while only 1% used it regularly. Regular
or occasional use was highest in the Baltic nations (Latvia, 12%;
Lithuania, 9%; Estonia, 8%) [2]. However, there are reports in the
literature about water-pipe tobacco smoking recently becoming a
trendy way to smoke and spreading rapidly in Europe, especially
among young people. In a survey of 2399 high-school students in
north-western London in 2011–2012, involving mainly deprived
and ethnic minority populations, the prevalence of current water-
pipe smokingwasmore than twice that of cigarette smoking – 7.6%
(95% conﬁdence interval (95%CI): 6.6–8.7%) versus 3.4% (2.7–4.2%)
– in students aged 12–18 years [9]. The proportion of students
(24%; 22.3–25.7%) reporting ever having tried water-pipe smoking
was higher than the proportion reporting ever having smoked
cigarettes (15.8%; 14.4–17.3%). The tobacco typically used in
water-pipe sessions is ﬂavoured with different aromas, and this is
believed to be in part responsible for the attractiveness of the
product [10].
With the exception of Sweden, smokeless tobacco is rarely used
in the EU Member States. The Eurobarometer survey [2] showed a
wide range in the proportions of respondents reporting ever having
tried smokeless tobacco (snus, chewing tobacco or nasal tobacco),
ranging from 44% in Sweden to 17% in Austria, 15% in Denmark and
Estonia, 2% in Romania, Hungary, Spain and Bulgaria and 1% in
Greece [2]. The PPACTE survey found that 1.1% of the European
population sampled (excluding Sweden) reported current use of
smokeless tobacco, whereas in Sweden the proportion was 20.7%
of men and 3.5% of women [5]. Use in Europe is clustered
geographically and is product-speciﬁc, as in the case of Sweden and
Norwaywhere the predominant product used is snus (moist snuff).
A 1989 EU tobacco directive (89/622/EEC) most recently ratiﬁed in
2014 reafﬁrmed the ban on exporting Swedish snus to other EU
countries [11]. However, manufacturing and sale of other
smokeless tobacco products not intended for mass marketing
and including oral (dipping or chewing) and nasal tobacco are
allowed within the EU. In certain countries chewing tobacco and
other smokeless tobacco products are used by ethnic groups
coming from parts of the world where these behaviours are
prevalent: for instance, the use of betel quid with tobacco in the
United Kingdom (UK) among migrant communities coming from
Central, East, South and South-East Asia [12–15]. A comprehensive
list of tobacco products used in Europe is given in Table 2.
1.3. Exposure to second-hand smoke (SHS) in Europe
1.3.1. Deﬁnition and exposure by country
SHS is deﬁned as the smoke emitted from the burning end of a
cigarette or from other combustible tobacco products, usually in
combinationwith smoke exhaled by the smoker [16]. The extent of
exposure to SHS in a country is directly related to the prevalence
of smoking and the existence, restrictiveness and enforcement of
policies banning smoking in public places and workplaces. The EC
Council Recommendation of 30 November 2009 on smoke-free
environments, based on Article 8 of theWorld Health Organization
Framework Convention on Tobacco Control (WHO FCTC),
demanded of EU Member States the implementation of smoke-
free environments in indoor public places and workplaces and in
public transportation by no later than November 2012. All EU
Member States have some form of smoke-free legislation, but the
Table 2
List of tobacco products consumed in Europe.
Smoked tobacco products. In Europe, manufactured tobacco products for smoking most frequently include cigarettes, cigars and cigarillos, ﬁne-cut tobacco for hand-
rolled cigarettes, and pipe tobacco.
Cigarette
[TD$INLINE]
Source: Image courtesy of hinnamsaisuy/FreeDigitalPhotos.net
Any roll of tobacco wrapped in paper or other non-tobacco material; ﬁlter-tipped or untipped;
also available ﬂavoured; approximately 8mm in diameter and 70–120mm in length.
Cigarettes usually contain blended tobaccos of different types. The type of tobacco used in these
products inﬂuences the composition of the smoke produced. An individual cigarette contains
approximately 1 g of tobacco and 1mg of nicotine.
Roll-your-own cigarettes
[TD$INLINE]
Source: Image courtesy of graurcodrin/FreeDigitalPhotos.net
Individually hand-rolled cigarettes made of ﬁne-cut loose tobacco wrapped in cigarette paper,
containing less tobacco than commercially manufactured types (approximately between
0.4 and 0.75 grams).
Cigar
[TD$INLINE]
Source: Image courtesy of Grant Cochrane/FreeDigitalPhotos.net
Any roll of tobacco wrapped in leaf tobacco or in any other substance containing tobacco. There
are different types: little cigars, small cigars (cigarillos), regular cigars, premium cigars. Some
little cigars are ﬁlter-tipped and are shaped like cigarettes.
Pipe tobacco
[TD$INLINE]
Source:  iStockphoto.com
A pipe is a device for smoking tobacco that consists of a chamber (the bowl) for the tobacco,
connected to the mouthpiece (the bit) by a thin hollow stem (the shank). Pipes are often
carefully treated, and loose tobacco for pipe smoking is blended to achieve ﬂavour nuances not
available in other tobacco products.
Hookah/water-pipe tobacco
[TD$INLINE]
Source:  iStockphoto.com
Awater-pipe is commonly used to smoke tobacco that is ﬂavoured or fermented with molasses
or other substances. The tobacco is heated by burning coal, and the smoke is cooled by passing
through the water and into the hose and mouthpiece, where it is inhaled.
Smokeless tobacco products, by mode of use. Tobacco leaves that are not burned for use can be used through the nose or mouth.
Nasal
[TD$INLINE]
Source:  iStockphoto.com
The tobacco is ﬁre-cured, then fermented and processed into a dry, powdered form, referred to
as dry snuff. Dry snuff is packaged and sold in small metal or glass containers. Used very rarely
in Europe (used in the United Kingdom), it is inhaled into the nostrils. Powdered dry snuff can
also be taken orally.
Oral Oral use of smokeless tobacco in Europe consists of placing tobacco in the space between the lip
or cheek and gum and either chewing or sucking it for a certain period of time. A chaw, which
refers to a portion of tobacco the size of a golf ball, is generally chewed, whereas a quid is usually
a much smaller portion and is held in the mouth rather than chewed. Newer smokeless tobacco
products are used in Scandinavian countries, such as the Swedish snus or Swedish moist snuff,
and consist of small pouches containing tobacco (portion-bag snuff). In Sweden, approximately
21% ofmen use smokeless oral tobacco. However, oral tobacco products are used by less than 2%
of the European population overall.
Loose leaf
[TD$INLINE]
Source:  iStockphoto.com
Consists of loose cigar tobacco leaves that are air-cured, stemmed, cut or granulated, and loosely
packed to form small strips of shredded tobacco.Most brands are sweetened and ﬂavouredwith
liquorice, and are typically sold in pouches. Loose-leaf tobacco is high in sugar content
(approximately 35%). A pinch of tobacco is placed between the cheek and lower lip, typically
towards the back of the mouth. It is either chewed or held in place. The saliva is spat out or
swallowed.
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Moist snuff/Snus
[TD$INLINE]
Source:  iStockphoto.com
The tobacco is either air-cured or ﬁre-cured, then processed into ﬁne particles (‘‘ﬁne-cut’’) or
strips (‘‘long-cut’’). Tobacco stems and seeds are not removed. Moist snuff is sold either loose or
packaged in small, ready-to-use pouches called packets or sachets. A pinch (called a dip) or a
pouch is placed and held between the lip or cheek and gum. The saliva may be swallowed or,
more commonly, spat out.
Swedish-type moist snuff (snus) consists of ﬁnely ground dry tobacco mixed with aromatic
substances, salts (sodium chloride), water, humidifying agents, and chemical buffering agents
(sodium carbonate). A pinch (called a dip) is placed between the gum and upper lip. The average
user keeps snuff in the mouth for 11–14h per day. In Sweden, the portions come in two doses
(regular and ‘‘mini-portions’’) or loose. The European Commission bans the sales of snus in the
European Union, with the exception of Sweden.
Betel quid with added tobacco
[TD$INLINE]
Source: N. Guha/IARC
Betel quid is commonly used by minority groups residing in Europe, particularly in the United
Kingdom among migrant communities arising from Central, East, South, and South-East Asia.
Betel quid with tobacco, commonly known as paan or pan, consists of four main ingredients: (i)
betel leaf, (ii) areca nut, (iii) slaked lime, and (iv) tobacco. Tobacco may be used in raw, sun-
dried, or roasted form, then ﬁnely chopped or powdered and scented or boiled, made into a
paste, and scented with rosewater or perfume. The ﬁnal product (quid) is placed in the mouth
and chewed.
Maras
[TD$INLINE]
Source: Image courtesy of M. Seydiog˘ullari
Maras is a type of smokeless tobacco that is widely used in the south-eastern region of Turkey,
especially in the cities of Kahramanmaras¸ and Gaziantep. First, sun-dried tobacco leaves are
powdered andmixed with the ash of wood, in particular oak, walnut, or grapevine. Then, water
is sprinkled onto the mixture for humidiﬁcation. A small amount of the mixture is applied
between the lower labial mucosa and gingiva for 4–5min. This procedure is repeated many
times during the day; some people even sleep with the powder in their mouths.
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legislation in the EU and other countries in Europe. A detailed
description of smoke-free regulations in place in the EU is available
at http://ec.europa.eu/health/tobacco/smoke-free_environments/
index_en.htm [18] or in the latest WHO report on the global
tobacco epidemic at http://www.who.int/tobacco/global_report/
en/ [19].
According to a survey commissioned by the EU in 2012, of more
than 12,000 people in the 27Member States at the time, more than
25% reported being exposed to SHS at least occasionally at work.
The overall proportion exposed in the EU-27 for more than 5 h/day
was 3% (5% of smokers and 1% of non-smokers) [2]. The overall
proportion reporting having seen smoking in restaurants and in
bars in the 6 months prior to the survey was 14% and 28%,
respectively. Country-speciﬁc estimates of exposure to SHS at
these venues in 2009 and 2012 in the EU-27 are shown in
Figs. 2 and 3. A trend towards decreased exposure to SHS is evident
from 2009 to 2012, although certain countries still have high
prevalence of exposure [17]. As there is wide variation in the
prevalence of smoking and the extent to which smoking is banned
in public and work settings among EU countries, the probability of
exposure to SHS varies substantially [18]. Also, as smoking tends to
be more prevalent in certain subgroups of the population, for
instance the less educated, exposure to SHS represents a risk factor
disproportionally present in those subgroups, possibly contribut-
ing to health inequalities [20].
1.3.2. SHS exposure at home
The home may be a place of frequent exposure if smokers
smoke at home. In theWomen in Europe against Lung Cancer and
Smoking (WELAS) study, a population-based telephone survey of
4977 women in 2008, the proportion responding that no smoking
was permitted inside the homewas 59.5% in France, 61.3% in Italy,
63.5% in Ireland, 74.4% in the Czech Republic and 87.0% in Sweden
[21]. In the PPACTE survey, conducted in 2010 and involving
about 18,000 adults living in 18 European countries, 62.2% ofrespondents reported that smoking was not allowed inside the
home (72.8% of non-smokers and 34% of current smokers) [22]. In
the few European countries included in the 2011 edition of the
Global Youth Tobacco Survey (GYTS), covering adolescents aged
13–15 years, the proportion responding that they lived in homes
where others smoked in their presencewas 66.9% inCroatia, 44.6%
in Latvia, 43.0% in the Czech Republic, 41.3% in Slovenia and 22.2%
in the Ukraine (Country Fact Sheets, GYTS, http://nccd.cdc.gov/
GTSSData/Ancillary/DataReports.aspx?CAID=1) [23].
2. Tobacco use and cancer risk
Tobacco is the major cause of cancer, and tobacco-attributable
cancer is entirely preventable. According to the WHO FCTC,
‘‘tobacco products’’ are wholly or partlymade of leaf tobacco as the
raw material and fabricated to be used for smoking, sucking,
chewing or snifﬁng [24]. Tobacco use exposes consumers to a
variety of carcinogens and other toxic agents while supplying
nicotine, an addictive substance in cigarette smoke and smokeless
tobacco products, which leads to long-term dependence on
tobacco use, and cumulative exposure to these toxicants. Contin-
ued exposure, in turn, causes cancer and other chronic diseases.
2.1. Carcinogens in tobacco, tobacco smoke and SHS
All tobacco products contain carcinogens. Some carcinogens are
constituents of the tobacco plant itself (i.e. tobacco-speciﬁc
nitrosamines [TSNA] – including N0-nitrosonornicotine [NNN]
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [NNK]) –
and most are formed when tobacco is burned (i.e. polycyclic
aromatic hydrocarbons [PAHs], speciﬁcally benzo[a]pyrene)
[16,25]. Processing, curing, ageing or storing tobacco can also
generate cancer-causing agents (i.e. volatile aldehydes, including
acetaldehyde and formaldehyde, and TSNA) [25,26]. Certain types
of carcinogens are found across the whole range of tobacco
products tested (i.e. TSNA), although their concentration varies
[(Fig._1)TD$FIG]
Fig. 1. Coverage of smoke-free legislation in place in various countries in Europe as of January 2013. (*) Total ban on indoor smoking; [TD$INLINE] ban on indoor smoking but provides
separate enclosed smoking rooms; (*) partial ban on indoor smoking, e.g. smoking zones or exemptions for certain categories of venues; () only recommendations, no bans
in place. Adapted from the Report on the implementation of the Council Recommendation of 30 November 2009 on Smoke-free Environments (2009/C 296/02) [17,18]. The
original ﬁgure displayed here includes a description of the speciﬁc features of smoking bans in place in each country listed. For brevity, we have omitted the long series of
speciﬁcations, which are available online at http://ec.europa.eu/health/tobacco/docs/smoke-free_implementation_report_en.pdf.
M.E. Leon et al. / Cancer Epidemiology 39S (2015) S20–S33S24substantially across products, while other types are predominantly
linked to how a product is used (i.e. benzene in tobacco smoke)
[16,25,26]. More than 70 agents in tobacco smoke have been
classiﬁed as carcinogenic to laboratory animals or to humans by
the International Agency for Research on Cancer (IARC); 16 of these
agents are considered carcinogenic to humans [25]. There are
additional suspected carcinogens in tobacco smoke which have
not been evaluated by the IARC. PAHs, TSNA, aromatic amines,
aldehydes, and certain volatile organic compounds are the main
agents through which tobacco smoke causes cancer [27].
Non-smokers breathing the smoke released into the air by
smokers and by lighted cigarettes are exposed to and metabolise
the same carcinogens that smokers inhale while pufﬁng
[16,28,29]. The concentrations of individual toxicants in SHS
during a given time period can vary depending on the number ofsmokers emitting SHS, the size of the placewhere smoking occurs,
the time elapsed since release into the air, and the environmental
conditions of the place. Studies comparing people exposed and
non-exposed to SHS indicate that the levels ofmetabolites of NNK
(e.g. total NNAL or 4-(methylnitrosamino)-1-(3-pyridyl)-1-buta-
nol), PAHs (e.g. hydroxypyrene) and nicotine are increased in the
urine of exposed subjects [30–32].
2.2. Summary of tobacco smoking and cancer risk
Cigarette smoking is the most harmful form of tobacco use,
causing the largest cancer burden. Based on an enormous body of
published literature, the IARC Monographs Programme has classi-
ﬁed tobacco smoking as a cause of cancers of the haematopoietic
system (namely myeloid leukaemia), cervix, colorectum, kidney,
[(Fig._2)TD$FIG]
Fig. 2. Exposure to second-hand tobacco smoke (SHS) in the EU-27 in 2009 and 2012 in eating establishments. From the European Commission [17,18].
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cavity, ovary, pancreas, pharynx (naso-, oro-, and hypo-pharynx),
stomach, ureter, and urinary bladder, as well as hepatoblastoma (in
the children of smokers). Cigarette smoking is the major cause of
lung cancer (see Section 2.8). There is also some evidence indicating
that tobacco smokingmay cause cancer of the breast and childhood
leukaemia (in the children of smokers) [16,25,33].
2.3. Summary of smokeless tobacco use and cancer risk
The IARC Monographs Programme has identiﬁed smokeless
tobacco as a cause of cancers of the oral cavity, oesophagus and
pancreas [16,26,33], and has also identiﬁed betel quid with added
tobacco as a cause of cancers of the oral cavity, oesophagus and
pharynx [16,33–35]. Smokeless tobacco has also been identiﬁed as
a cause of pre-malignant lesions in the oral cavity [26]. However,
one type of smokeless tobacco, Swedish snus, is associated with a
much lower risk of oral cancer. Studies from Sweden have not
shown excess risk of oral cancer in associationwith snus use, while
excess risk of oesophageal and pancreatic cancers have been
reported in some studies [36].
2.4. Summary of SHS exposure and cancer risk
The IARC Monographs Programme has classiﬁed second-hand
tobacco smoke as a cause of lung cancer and a possible cause of
cancersof the larynxandpharynx [16,25,33].Othercancer siteshave
been associated with SHS, although the evidence is less consistent.
Parental smoking causes hepatoblastoma in children [16].
[(Fig._3)TD$FIG]Fig. 3. Exposure to second-hand tobacco smoke in the EU-27 in 2009 and 202.5. Major determinants of cancer risk due to tobacco smoking
In 2012, lung cancer ranked second and third among incident
cancers in men and women, respectively, in the combined 27 EU
Member States and Croatia, and contributed substantially to the
overall burden of tobacco-attributable cancers [37]. Lung cancer is
the most common cause of death from cancer in Europe
[38]. Smoking is associated with an increased risk of squamous-
cell carcinoma, adenocarcinoma, large-cell carcinoma and small-
cell carcinoma of the lung [16]. The main factors that drive the
remarkably high cancer risk associated with smoking are duration
and intensity. Epidemiological studies conducted in the UK and the
United States of America (USA) indicate that the number of years
that a person smokes (self-reported) is more strongly associated
with lung cancer risk than intensity of use, and that this association
holds for men and women at different ages [16]. A comprehensive
list of epidemiological studies conducted all over the world
reporting on the effect of duration of smoking on lung cancer risk
are available in the IARC Monographs Volumes 83 (2004) [25] and
100E (2012) [16]. Also, based on self-reporting in epidemiological
studies, the risk of lung cancer increases with increasing daily dose
(up to 15–20 cigarettes per day), but the effect levels off at very
high intensities. This relationship has also been detected for
cancers of the bladder, oral cavity, oesophagus and pancreas
[16]. However, data from cohort studies examining risk of lung
cancer associated with serum cotinine as a biomarker of exposure
demonstrate a linear increase in lung cancer risk with rising
concentration of cotinine [16], thereby not supporting the
levelling-off effect at the higher doses of smoking reported above.12 in drinking establishments. From the European Commission [17,18].
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cotinine and a metabolite of the TSNA carcinogen NNK; smokers
with similar self-reported smoking histories differ substantially in
lung cancer risk based on the concentrations of urine cotinine and
NNAL [16,39].
2.6. Combined effect of smoking and alcohol consumption
Alcohol consumption increases the already high risk of cancers
of the oral cavity, oropharynx, larynx and oesophagus associated
with smoking. This effect appears to be synergistic in that the
risk of cancer at these sites rises progressively with increasing
alcohol consumption among smokers. Several mechanisms have
been reported to contribute to these observed interactions,
including: the increased permeability of tobacco-smoke carcino-
gens through the oral mucosa in the presence of alcohol; the
increased solubility of tobacco-smoke carcinogens in ethanol;
increased acetaldehyde production from alcohol oxidation by oral
bacteria; alcohol-derived increased induction of CYP2E1 (an
enzyme member of the cytochrome P450 oxidase system involved
in the metabolism of xenobiotics in the body) in the liver, which
can elevate the amount of toxicmetabolites during themetabolism
of carcinogens present in tobacco smoke (e.g. benzene); alcohol-
induced increased generation of CYP3A4 and CYP1A2 (other
members of the cytochrome P450 oxidase system), which can
activate tobacco carcinogens such as NNK; and alcohol-induced
inhibition of the family of CYP enzymes, which could result in
locally increased accumulation of toxic agents by reduced
metabolic activation [16,40].
2.7. Major determinants of smokeless-tobacco-associated cancer risk
Determinants of cancer risk are product-type-speciﬁc, and
dose–response relationships have not been systematically docu-
mented in association with cancers of the oral cavity, oesophagus
and pancreas in countries where dipping or chewing tobacco are
traditionally used; hence the data are limited. In snuff users in the
USA who did not report smoking or alcohol consumption, an
increased risk of cancer of the gums and oral mucosa has been
reported with increasing duration of use, in a dose–response
manner. The dose–response relationship has not been observed for
all head-and-neck subsites or in Swedish studies focusing on oral
cancer. The risk of pre-cancerous lesions in the oral cavity has been
reported to increase with duration and intensity of use of snuff or
of chewing tobacco, while the dose–response relationship appears
to be stronger with snuff use. An increase in the prevalence of
lesions has been reported with increased number of hours of
use per day, quantity of tobacco used, and duration of use. The
severity of lesions is also correlated with duration of use
[16,26]. Modest elevation of risk of oesophageal squamous-cell
carcinoma with long duration of use has been reported in one
Swedish study (odds ratio [OR] = 1.4, 95%CI = 0.9–2.3, for 25 or
more years of use compared with never-users) [41]. One of the
major challenges to improved characterisation of the determinants
of cancer risk associated with smokeless tobacco is the relatively
small number of studies compared with the large number of
smokeless tobacco products available on the market, including
commercially manufactured products as well as small-scale
informal production; the constituents of these products –
including carcinogens – vary substantially.
2.8. Cancer burden caused by smoking in Europe
Cigarette smoking causes cancer in multiple organ sites in
humans and accounts for the premature death of more than half of
long-term smokers [16,42–44]. The percentage of cancers causedby smoking is highest in the lung (82%) and the larynx (84%)
[45]. These fractions indicate the proportions of cancers that could
be prevented by eliminating smoking. In 2012, in the EU-27 and
Croatia combined, the age-standardised (World standard) overall
cancer rate was estimated to be 273.5 cases per 100,000
population, with 45.1 cases per 100,000 for lung cancer in men
and 18.2 cases per 100,000 for lung cancer in women [37]. The risk
of dying from lung cancer is 20–25 times as high in men and
women who smoke as in their non-smoking counterparts
[46]. Further, the overall risk of death in smokers is 2–3 times
as high as that in never-smokers, with an average loss of 10 years of
life expectancy [47].
In 2012 there were 312,645 cases of lung cancer in the pooled
population of the EU-27 and Croatia [37]. For several countries
in Europe there has been a progressive decline in the rate of
lung cancer in men, mainly following a gradual decrease in
smoking prevalence inmen in the population. In 2013, for the ﬁrst
time in 80 years, the prevalence of smoking in England was
recorded to be below 20% (19.3%, 95%CI = 18.8–19.8%)
[48]. According to the 2012 Globocan estimates, the crude and
age-standardised (world standard) lung cancer incidence rates in
men in the EU-27 plus Croatia were highest for Hungary, with
124.7 per 100,000 and 76.6 per 100,000 respectively, and lowest
for Sweden, with 40.7 per 100,000 and 19.4 per 100,000,
respectively (Fig. 4) [37]. In women, the estimated crude and
age-standardised lung cancer incidence rates were highest in
Denmark (80.3 and 37.6 per 100,000) and lowest in Lithuania
(15.9 and 7.2 per 100,000) (Fig. 4). The highest rates observed in
European women are lower than the highest rates reported in
men, and the lowest rates in women are considerably lower than
the lowest rates in men. Overall, in the past, women in Europe
have not smoked for as long or as much as men have. But this
trend is changing, regrettably, in several countries in Europe. In
some, lung cancer rates have been similar in men and women in
recent times (e.g. Iceland and Denmark) and are increasing.
In several other countries, although lung cancer rates in women
have been lower than those in men, they have been increasing
since 1975, with projections for further rises (e.g. France, Italy,
Spain, Switzerland, and The Netherlands) [49]. In Sweden, the
rates inmen andwomen are similar (see Fig. 4). Because there is a
long lag time between the initiation of smoking and the
appearance of overt lung cancer, current rates of lung cancer
might not match current levels of smoking in the population in
any given country.
Cancers atmany organ sites, other than the lung, are also caused
by smoking. Agudo et al. [45] calculated the attributable fraction of
those other cancers due to smoking using data from a large
European cohort study. They reported that these proportions were
highest (above 80%) for cancer of the larynx, between 50% and 20%
for cancers of the lower urinary tract and other respiratory and
digestive cancers, and below 20% for all other cancers linked to
smoking. Overall, they calculated that between 32% and 37% of
these cancers are caused by smoking [45]. This study highlights the
amount of damage that smoking causes in the European
population, but it similarly stresses how much disease can be
prevented by quitting smoking.
Smoking also has a harmful effect on non-smokers, speciﬁ-
cally individuals exposed to SHS. In the UK, breathing SHS is
estimated to cause 14–15% of lung cancers in non-smokers
[50]. In countries with smoking prevalence higher than that in
the UK, the fraction of lung cancers in non-smokers caused
by SHS is expected to be higher, particularly in the presence of
non-comprehensive or weak smoke-free policies. Using esti-
mates of exposure from the 1990s, WHO estimated that in
2004 there were 3850 lung cancer deaths in Europe attributable
to SHS exposure [51].
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Fig. 4. Estimates of age-standardised incidence rates of lung cancer in 2012 (world standard population) in the European Union (EU-27 and Croatia). European variation in
estimates of national age-standardised lung cancer incidence rates (per 100,000) among men and among women. Adapted from Ferlay et al. [37]. The data displayed are
available at Globocan 2012 after requesting speciﬁc analysis and thus graphs are not readily shown. Country-speciﬁc crude and age-standardised incidence rates are
available from http://globocan.iarc.fr.
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A recent report from the United States National Cancer Institute
and the Centers for Disease Control and Prevention has estimated
that more than 300 million people in the world are smokeless
tobacco users, stressing that South-East Asia has the majority of
users and also has the highest rates of oral cancer in the world
[52]. However, as stated above, smokeless tobacco products vary
geographically and do not all entail the same cancer risk.
Considering that snus is the predominant smokeless tobacco
product used in Sweden, the EU country with the highest
prevalence of smokeless tobacco use, only the cancer-related
burden associated with snus in that country is provided here. The
above-cited 2014 report [52] estimated that 13.5% of oesophageal
cancers and 17.2% of pancreatic cancers in men in Sweden are due
to snus use, while in women the estimates are 4.0% and 5.3%,
respectively, although these estimates are based on only one
review [36] and the report noted that there was some uncertainty
associated with the values. Other types of smokeless tobaccoproducts with higher toxicity are used by ethnic minorities from
South-East Asia living in Europe [14].
2.10. Reduction in the risk of cancer and cancer death after smoking
cessation
The risk of developing or dying from lung cancer is
substantially lower in former smokers than in those who
continue smoking. Within 5–9 years after cessation, the risk of
lung cancer in former smokers decreases progressively with
increasing time since quitting compared with the risk in
continuing smokers [44]. This same pattern has been observed
for the majority of the cancers associated with smoking, with
variations in the length of time after cessation needed to observe
a decrease in risk. Epidemiological data clearly support this for
cancer of the larynx, pharynx and oral cavity, squamous-cell
carcinoma of the oesophagus, stomach, pancreas, bladder and
squamous-cell carcinoma of the cervix. The data are limited or
inadequate for cancers of the liver, nasopharynx, sinonasal
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Fig. 5. Cumulative risk of death from lung cancer in men in the United Kingdom for
continuing smokers and for former smokers, according to the age when quitting
(death rates in 1990 are shown). From Peto et al. [56].
M.E. Leon et al. / Cancer Epidemiology 39S (2015) S20–S33S28cancer and adenocarcinoma of the oesophagus, and for myeloid
leukaemia [44].
2.10.1. Reduced cancer incidence and mortality risk with younger age
at cessation
Studies comparing the risk of lung cancer, cancer death or total
mortality in former and current smokers with the risk in never-
smokers have shown the signiﬁcantly lowered risk of any of these
adverse health outcomes in those who have quit, with the risk
diminishing progressively with decreasing age at smoking cessa-
tion, and approximating – although not reaching – the risk in
never-smokers for those quitting at a very young age [44]. The
beneﬁts of quitting smoking in relation to reduced cancer or total
mortality have been addressed in multiple epidemiological
studies, with strong data in men documented in several countries,
including the UK, Poland and the USA [42,45,46,53,54], and more
recently in a large prospective study of women in the UK
[55]. These studies are consistent in showing similar trends after
smoking cessation. Compared with never-smokers, the relative
risk of lung cancer death in women who quit smoking prior to
25 years of age, or at age 30, 40 or 50 years has been reported to be
1.56 (1.03–2.37), 1.84 (1.45–2.34), 3.34 (2.76–4.03) and 5.91
(5.01–6.97), respectively, with a risk substantially lower than that
observed in women who continue to smoke, who show a 20-fold
higher risk of lung cancer death than never-smokers. Women
who stop smoking at the age of about 30 or 40 years avoid most
of the excess risk observed in women who don’t quit, a decrease
of 97% and 90% of the risk, respectively, according to Pirie et al.
[55]. Smokers die prematurely, losing on average about 10 years
of life expectancy. Fig. 5 shows the cumulative risk of death from
lung cancer in men in the UK for continuing smokers and for
former smokers according to the age when they quit, showing
death rates in 1990 [56]. More recent studies continue to
document the health beneﬁts of quitting smoking, showing
greater reductions in total mortality risk [54,55] or lung cancer
mortality risk [55] with decreasing age at cessation in the USA
and the UK.
3. Effective interventions to reduce the risk of cancer caused by
smoking
The best option for individualswhowant to take personal direct
action to reduce their risk of cancer from tobacco is not to smoke
and generally not to use any form of tobacco, as well as to avoid
exposure to second-hand smoke by making their homes smoke-
free and advocating for smoke-free laws for indoor workplaces and
public places.
3.1. Quitting smoking
There are interventions available with demonstrated efﬁcacy as
smoking cessation aids; these include pharmacotherapy and
behavioural support. The most frequently used effective pharma-
cotherapy includes medicinal nicotine or nicotine replacement
therapy (NRT), antidepressant therapy using bupropion, and use of
nicotine-receptor partial agonist medications, including vareni-
cline and cytisine. Pharmacotherapy use can be associated with
side-effects, but these are minor compared with the health effects
caused by continued smoking.
Behavioural support commonly includes advice on strategies to
plan a quit attempt, to manage nicotine cravings and withdrawal
symptoms, to select pharmacotherapy and other information to
help the smoker manage the stress related to smoking cessation.
This advice can be dispensed in different modalities: individually
or collectively, face-to-face, via the telephone or through electronic
channels.Scientiﬁc evidence indicates that the most effective interven-
tion to help smokers quit is the use of a combination of
pharmacotherapy and behavioural support. Providing behavioural
support in addition to pharmacotherapy increases the proportion
of successful attempts with at least a 6-month abstinence
compared with pharmacotherapy with no, minimal or less
intensive support for smokers (relative risk [RR] = 1.16,
95%CI = 1.09–1.24) [57].
3.1.1. Pharmacotherapy
NRT is available for different routes of administration (transder-
mal patch, nasal spray, chewing gum, oral spray and ﬁlm strips,
inhaler and sublingual tablets/lozenges and other forms) and
dosages (16-h and 24-h transdermal patches; 2 or 4 mg chewing
gum; 1, 1.5, 2 or 4 mg nicotine lozenges; 2 mg sublingual tablets
and others). NRT is commonly available over the counter in Europe,
but it can also be medically prescribed. All of the commercially
available forms of NRT can help smokers increase their chances of
successfully stopping smoking for at least 6 months. Recent
systematic reviews have summarised the ﬁndings of multiple
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other types of pharmacotherapy, when using more than one
formulation of NRT and in smokers who decide to quit abruptly
or by progressively reducing the amount smoked daily. Results of
the clinical trials evaluating these comparisons are available in the
reviews by Stead et al. [57] and by Moore et al. [58].
In subjects intending to quit abruptly, all types of NRT have
shown efﬁcacy in maintaining abstinence for at least 6 months
compared with no treatment (RR = 1.60, 95%CI = 1.53–1.68). Also,
use of a combination of NRT products proved to be more effective
than using a single formulation type (RR = 1.34, 95%CI = 1.18–
1.51). NRT is also effective in aiding smokers who prefer to quit by
gradually reducing the number of daily cigarettes until achieving
sustained abstinence as opposed to quitting abruptly (6-month
abstinence, RR = 2.06, 95%CI = 1.34–3.15). Studies comparing NRT
with othermedicinal cessation products showed that NRT seems to
be as effective as bupropion (RR = 1.01, 95%CI = 0.87–1.18),
whereas the combination of NRT plus bupropion seems to confer
additional beneﬁt compared with bupropion alone (RR = 1.24,
95%CI = 1.06–1.45, based on four trials reported by Stead et al. [57])
and a substantial increased effect compared with placebo (a more
than two fold increase in cessation; RR = 2.61, 95%CI = 1.65–4.12).
Adverse effects reported in association with NRT are minimal and
type-speciﬁc, such as skin irritation from patches and irritation in
the oral cavity from use of gum or tablets.
Bupropion is an atypical antidepressant available by medical
prescription in most European countries. A usual treatment
regimen includes 300 mg/day for 7–8 weeks, beginning 1 week
before the planned quit date. The original systematic review by
Hughes [59] and its most recent update [60] summarise the
ﬁndings of the trials assessing this type of cessation aid. The pooled
estimates from these trials demonstrate that bupropion is effective
in maintaining abstinence for 6 months (RR = 1.81, 95%CI = 1.51–
2.16) or even longer (12 months, RR = 1.64, 95%CI = 1.46–1.84)
compared with placebo. Also, bupropion appears to be as effective
as NRT in the form of the transdermal patch (RR = 1.26,
95%CI = 0.73–2.18), but these results come from only three trials.
Compared with varenicline, bupropion seems to be less effective, a
conclusion based on very few trials (RR = 0.66, 95%CI = 0.53–0.82).
The summary measure from six trials indicates that bupropion
plus NRT is not more effective than NRT alone (RR = 1.26,
95%CI = 0.73–2.18). Other antidepressants compared in random-
ised trials have not shown efﬁcacy in maintaining abstinence from
smoking for 6 months. Adverse health effects have been reported
in association with use of bupropion. There is a risk of seizures of
about 1 in 1000 users, and there is suggestion of increased risk of
suicide.
Varenicline is a nicotine-receptor partial agonist, which is
available to smokers by medical prescription in most European
countries. A typical treatment regimen consists of 11 weeks of
administration starting 1week before the planned date for quitting
at a dose of 1 mg/day and subsequently at 2 mg/day until the end of
treatment. Results attesting to the efﬁcacy of this type of product
have been abstracted from the systematic review by Cahill et al.
[61]. Varenicline at the standard dose increases the chance
of successful smoking abstinence for 6-month (RR = 2.27,
95%CI = 2.02–2.55) and 12-month (RR = 4.91, 95%CI = 2.56–9.42)
intervals, an increase of between two- and almost ﬁve-fold
compared with placebo. More participants quit successfully with
varenicline than with bupropion (RR = 1.52, 95%CI = 1.22–1.88).
Two open-label trials of varenicline versus NRT have suggested
equivalence between the products (RR = 1.13, 95%CI = 0.94–1.35).
The main adverse effect reported in association with use of
varenicline is nausea (mostly mild to moderate, and usually
subsiding over time). Lower dose regimens also confer beneﬁts for
cessation while reducing the incidence of collateral health effects.Cytisine, another nicotine-receptor partial agonist, has been
available in a few countries in central and eastern Europe for
decades [62]. The treatment regimen usually lasts 4 weeks and
starts 1 week before the planned quit date, with dosage decreasing
progressively. Cytisine increases the chance of quitting smoking,
although absolute quit rates have been modest in at least one
earlier trial: 8.4% in the treatment arm versus 2.4% in the placebo
arm at 12 months [63]. A recently reported randomised trial
conducted in New Zealand has reported 1-month (40% versus 31%)
and 6-month (22% versus 15%) quit rates signiﬁcantly higher in the
cytisine arm than in the NRT arm, with longer elapsed time from
quit date to relapse in the cytisine arm (53 days versus 11 days)
[64]. These quit rates are superior to those reported in earlier trials
at 6 months, while the efﬁcacy at 12 months was not reported in
the recent trial. Self-reported adverse health effects were more
frequent in the cytisine arm, with nausea, vomiting and sleep
disorders being the most common complaints. In the earlier trial
by West et al. [63], gastrointestinal complaints were more
frequently reported in the cytisine arm of the trial.
An overview of 12 Cochrane reviews was published in 2013,
including a network meta-analysis which allows for indirect
comparisons between different treatments assessed in separate
trials [65]. This synthesis concluded that NRT, bupropion and
varenicline all improve the chance of quitting. Use of a combina-
tion of NRT is as effective as varenicline, and more effective than
using a single type of NRT. Based on the evidence available at the
time of that publication, the safety proﬁles of these treatment
options were not discouraging, but nevertheless continued moni-
toring and research on the safety of varenicline was recommended,
aswell as theevaluationof thepotential of cytisineasa safe, effective
and affordable treatment option in smoking cessation [65]. Cytisine
is more affordable than varenicline.
3.1.2. Behavioural support
This type of support can include advice by physicians and other
health professionals, counselling, incentives, self-help and stage-
based interventions and motivational interviews, among other
possibilities. Based on the systematic review by Stead et al. [66] on
physician advice, brief and simple advice given by physicians to
their smoking patients consisting of verbal instructions with a
‘‘stop smoking’’ message is effective in helping people to stop
smoking compared with the control group (RR = 1.76,
95%CI = 1.58–1.95). Interventions based on advice of different
intensities have been compared, suggesting a probable beneﬁt
from the more intensive interventions compared with briefer
advice, although subgroup analyses suggest that this might be
small or non-existent in unselected smokers, but with a larger
impact in high-risk groups.
Counselling, whether individual, group or telephone-based, has
been evaluated as a smoking cessation intervention. Individual
counselling is effective in helping people to stop smoking. For
example, studies evaluating counselling consisting of more than
10 min of face-to-face contact versus minimal counselling have
found increased success in abstinence for at least 6 months
(RR = 1.39, 95%CI = 1.24–1.57). NRT plus individual counselling
increases the chance of quitting smoking and maintaining
abstinence for 6 months compared with NRT alone (RR = 1.27,
95%CI = 1.02–1.59) [67]. Group counselling includes discussion of
motives for group members’ decisions and their emotional
experiences, presentation of information and teaching of new
skills to achieve and cope with cessation. Group programmes may
be led by professional facilitators such as clinical psychologists,
health educators, nurses or physicians, or occasionally by
successful users of the programme. The implementation of
smoking cessation programmes in groups has been a popular
method of delivering behavioural interventions. These include
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control and cognitive-behavioural interventions. There may be a
speciﬁc therapeutic beneﬁt of the group format in giving people
who smoke the opportunity to share problems and experiences
with others attempting to quit. Group therapy is better than self-
help (RR = 1.98, 95%CI = 1.60–2.46) [68].
Telephone counselling may supplement face-to-face support,
or substitute for face-to-face contact as an adjunct to self-help
interventions or pharmacotherapy. Counselling may be helpful in
planning a quit attempt, and helping to prevent relapse during the
initial period of abstinence [69]. Telephone counselling may be a
way of providing individual counselling more cheaply. Telephone
contact can be timed to maximise the level of support around a
planned quit date, and can be scheduled in response to the needs of
the recipient. Telephone counselling can be proactive or reactive.
In a proactive approach, the counsellor initiates calls to provide
support in making a quit attempt or avoiding relapse. This can be
offered as part of an intervention, including face-to-face counsel-
ling, or provided as an adjunct to a mailed self-help programme or
to pharmacotherapy. Reactive counselling, in contrast, is available
on demand to people calling speciﬁc services, quitlines, helplines
or hotlines. These telephone services may offer information,
recorded messages, personal counselling or a mixture of compo-
nents. In the systematic review by Stead et al. [70], those who had
initiated contact with the quitline and who received multi-session
proactive call-back counselling had a 40% increased likelihood of
cessation and abstinence for at least 6 months compared with
subjects who received only self-help materials or brief counselling
during a single call (RR = 1.37, 95%CI = 1.26–1.50). There is
evidence of a dose–response effect; one- or two-call protocols
(RR = 1.07, 95%CI = 0.91–1.26) are less likely to provide a measur-
able beneﬁt compared with donation of self-helpmaterials or brief
counselling at a single call. Three or more calls increase the odds of
quitting compared with a minimal intervention such as providing
standard self-help materials or brief advice, or compared with
pharmacotherapy (RR = 1.34, 95%CI = 1.23–1.47). Telephone qui-
tlines provide important access to support for smokers, and call-
back counselling enhances their usefulness [70,71]. More intensive
behavioural support is likely to provide some additional beneﬁt
(four to eight contacts versus pharmacotherapy alone, RR = 1.25,
95%CI = 1.08–1.45).
3.2. Protecting against SHS at home
There is sufﬁcient evidence that smoke-free policies at home
diminish exposure of children to SHS [72]. In the households of
smokers, adoption of a smoke-free home will reduce exposure to
SHS in children, a vulnerable group whose exposure typically
depends on parental smoking. These studies have measured
exposure in different ways, some quantifying the number of hours
of exposure and others biomarkers of exposure in saliva, urine,
serum or hair (i.e. cotinine or nicotine). The study byMatt et al. [73]
in the USA illustrates, consistently, the occurrence and level of
exposure to SHS in children living in households with varying
smoking exposure and SHS-restriction proﬁles. In this comparison,
determinations in three different groups of families were made:
those with no smoking adults, those with at least one adult smoker
in the family but smoking only outside of the home or when the
childrenwere not present, and those with at least one adult smoker
but no restrictions on smoking. Determinations of exposure
included nicotine in household dust, in indoor air or on household
surfaces, and in infant hair as well as cotinine levels in infant urine
and hair. Infant urine cotinine concentrations were 0.32 ng/ml
(95%CI = 0.19–0.47) in the families with no smokers, 2.88 ng/ml
(95%CI = 1.22–5.79) in the families with smokers but smoking
restrictions in the home, and 13.02 ng/ml (95%CI = 8.01–20.81) inthe families with smokers and no restrictions. Similarly, infant
hair cotinine and nicotine concentrations were 0.08 ng/mg
(95%CI = 0.05–0.11) and 0.53 ng/mg (95%CI = 0.25–0.86), 0.52 ng/
mg (95%CI = 0.20–0.92) and 2.65 ng/mg (95%CI = 1.10–5.34), and
1.05 ng/mg (95%CI = 0.55–1.72) and 5.95 ng/mg (95%CI = 3.25–
10.37), respectively, in the three groups of families. Furthermore,
no nicotine was detected on surfaces in the living room or the
infant’s roomin the familieswithout smokers,while in theother two
groups of families the following level of contamination was
detected: the mean surface nicotine concentrations in the living
room and in the infant’s room, respectively, were 10.08mg/m2
(95%CI = 0.01–21.10) and 8.19mg/m2 (95%CI = 2.69–14.98) in
households with smokers but smoking restrictions and 51.33mg/
m2 (95%CI = 19.17–32.16) and 41.85mg/m2 (95%CI = 24.71–59.09)
in households of families with smokers and no smoking restrictions
inside the home [72,73]. This study shows that the best protection
from exposure to SHS is not to smoke, while adoption of smoking
restrictions in the households of smokers can reduce exposure
to SHS.
There is sufﬁcient evidence that smoke-free policies at home
lead to reductions in smoking among continuing smokers.
Restricting smoking to outside the home imposes a barrier to
smoking ad libitum and generates the inconvenience of having to
leave the home in order to smoke. This mechanism can postpone
the act of smoking, which generally leads to a reduction in the
number of cigarettes smoked per day in adult smokers [72]. Seven
longitudinal studies examining the effect of home smoking
restrictions on smoking behaviour have found that smokers in
smoke-free homes are more likely to quit or progress towards
cessation and less likely to relapse [74–80]. Similarly, several of
these studies also assessed the level of consumption among
smokers in both types of households, ﬁnding a reduction in the
number of cigarettes smoked that was larger in smokers living in
smoke-free homes than in those living in homes without smoking
rules [76–79]. Cross-sectional studies have also addressed
smoking cessation and level of consumption in continuing smokers
in homes according to the presence of smoking rules. Many of
these studies found signiﬁcantly lower consumption andmore quit
attempts in smokers living in homes with smoking restrictions
than in those living in households without them [72]. In addition,
evidence from cross-sectional studies suggests that adolescent
offspring of non-smoking parents living in smoke-free homes are
less likely to start smoking than similar adolescents living in
households where there are no explicit rules against smoking
inside the home [72].
Although there has been a time trend of increased adoption of
smoke-free policies at home among smokers, non-smokers
continue to be exposed to SHS at home in many parts of Europe,
and thus there is room for a greater adoption of smoke-free
homes. For instance, a greater proportion of children with
smoking parents lived in smoke-free homes after the introduc-
tion of the 2007 ban on smoking in enclosed public places in
England (48.1% in 2008) than before the ban (30.5% in 2006)
[81]. Yet these ﬁgures indicate that further reductions in
exposure could have been achieved at the time in the households
of smokers, and particularly in deprived households, where
exposure to SHS tends to be higher [82]. After the introduction of
the smoke-free policy in England, there was an increase in the
adoption of smoke-free homes, and the ban did not displace
exposure to SHS to the home [81].
3.3. Protecting against SHS in indoor workplaces and public places
Article 8 of the WHO FCTC indicates that countries should
adopt and implement effective legislation to protect citizens
from exposure to tobacco smoke in indoor workplaces, in indoor
Box 1. European Code Against Cancer.
EUROPEAN CODE AGAINST CANCER
12 ways to reduce your cancer risk
1. Do not smoke. Do not use any form of tobacco
2. Make your home smoke free. Support smoke-free policies in your
workplace
3. Take action to be a healthy body weight
4. Be physically active in everyday life. Limit the time you spend sitting
5. Have a healthy diet:
 Eat plenty of whole grains, pulses, vegetables and fruits
 Limit high-calorie foods (foods high in sugar or fat) and avoid sugary
drinks
 Avoid processed meat; limit red meat and foods high in salt
6. If you drink alcohol of any type, limit your intake. Not drinking alcohol is
better for cancer prevention
7. Avoid toomuch sun, especially for children. Use sun protection. Do not use
sunbeds
8. In the workplace, protect yourself against cancer-causing substances by
following health and safety instructions
9. Find out if you are exposed to radiation from naturally high radon levels in
your home; take action to reduce high radon levels
10. For women:
 Breastfeeding reduces the mother’s cancer risk. If you can, breastfeed
your baby
 Hormone replacement therapy (HRT) increases the risk of certain
cancers. Limit use of HRT
11. Ensure your children take part in vaccination programmes for:
 Hepatitis B (for newborns)
 Human papillomavirus (HPV) (for girls)
12. Take part in organised cancer screening programmes for:
 Bowel cancer (men and women)
 Breast cancer (women)
 Cervical cancer (women)
The European Code Against Cancer focuses on actions that individual citizens
can take to help prevent cancer. Successful cancer prevention requires these
individual actions to be supported by governmental policies and actions.
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other public places. The article focuses on three principles: 100%
smoke-free environments as opposed to implementing non-
smoking rooms; universal protection from SHS reaching all
people; and smoke-free laws, in contrast to voluntary interven-
tions to reduce exposure to SHS [24]. The overwhelming majority
of the evidence documents the substantial decline in exposure to
SHS in indoor public settings after the introduction of smoke-free
policies, with concomitant reductions in respiratory symptoms in
workers, and quitting smoking or reductions in cigarette con-
sumption among continuing smokers. Implementation of smoke-
free legislation that bans smoking in all, or virtually all, indoor
workplaces has shown reductions in SHS by 80–90% in venues
where smoking was common indoors before the bans, such as bars
and restaurants [72]. The drop in exposure to SHS in hospitality
venues has been sustained over time in the majority of countries
implementing comprehensive laws. In France, for instance, the
percentage of bars where indoor smoking occurred went from
95.9% before the 2008 smoking ban to 3.7% a few months after the
ban and to 6.6% 4 years later. In restaurants, similar determinations
went from 64.7% before the ban to 2.3% and 1.4%, respectively
[83]. In France, smoking in workplaces decreased from 42.6%
before the ban to 19.3% immediately after the ban and to 12.8% in
2012 [83]. The decrease in exposure to SHS has been greater in
workers in the hospitality industry than in the general population.
The reduction in exposure to SHS after the implementation of
comprehensive smoke-free laws is estimated to be about 80–90%
in workplaces and 40% at the population level as revealed in a
comprehensive study completed in Scotland [72].
Many studies have reported a signiﬁcant decline in the rate of
hospital admissions for cardiovascular events after the introduc-
tion of smoke-free laws [84–90]. The meta-analysis by Mackay
et al. [91] reports a 10% decrease in the incidence of acute coronary
events after the introduction of smoke-free laws (RR = 0.90;
95%CI = 0.86–0.94). Smoke-free legislation is expected to have a
signiﬁcant role in the reduction of lung cancer incidence in non-
smokers in future decades; at present, it is too early to assess this
effect as most smoke-free policies have been implemented
recently [72].
4. Justiﬁcation of recommendations
Smoking is a well-known major cause of cancer. Despite the
known smoking-associated detrimental effects to health, almost
28% of adults in the EU smoke. Hence, the following recommen-
dation was developed for the European Code Against Cancer: ‘‘Do
not smoke’’.
The overall European prevalence of current use of smokeless
tobacco products is almost 2%, and is higher in some countries
(see above). Although snus is associated with much lower risk of
some forms of cancer compared with other types of smokeless
tobacco, there is evidence that smokeless tobacco products overall
cause cancer. Hence, the following recommendation was devel-
oped: ‘‘Do not use any form of tobacco’’.
Smoking generates SHS, another well-known cause of cancer,
and inhalation of SHS by non-smokers is still common in indoor
workplaces and public places, and even more so in the homes of
smokers. Hence, the recommendations for individual action
to make homes smoke-free and to support smoke-free policies
in the workplace were developed. The presence of smokers in a
home increases the risk of smoking initiation, especially in
adolescents, and reduces the likelihood of stopping smoking
[72,92–94].
The impact of reduced prevalence of tobacco use, and in
particular cigarette smoking, will be reﬂected not only in
decreased cancer incidence and mortality but also in reducedmorbidity and mortality due to chronic obstructive pulmonary
disease (COPD), coronary heart disease, cerebrovascular disease
and other health outcomes with more acute onset, such as the
effects of smoking during pregnancy and the exacerbation of
asthma, among other conditions [95].
Reduced smoking at the population level and comprehensive
smoke-free laws will lead to decreased exposure to SHS in public
places and workplaces as well as in the home, with concomitant
protection of non-smokers from the harmful effects of SHS.
Furthermore, in an environment where the tobacco industry
targets individuals to try its products and lobbies local or national
governments to support its economic interests, the protection of
the health of the individual from tobacco needs a comprehensive
approach as mandated by the WHO FCTC, which deﬁnes tobacco
control as a domain for government regulation for the protection
of the individual and the overall population [24].
Overall, the tobacco-related recommendations for individual
action in the 4th edition of the European Code Against Cancer,
based on the available scientiﬁc evidence, are:
‘‘Do not smoke. Do not use any form of tobacco.’’
‘‘Make your home smoke-free. Support smoke-free policies in
your workplace.’’
The last part of the second recommendation encourages
individuals to require governmental action to protect them from
tobacco smoke. Other individual actions people can follow to
reduce their risk of cancer are listed in Box 1.
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